Stroke/Vascular Neurology News

BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, cerebral embolic protection did not decrease incidence of periprocedural stroke.

In this edition, new cannabinoids hold promise for medical applications; Theranica secures $45 million for migraine treatment device and more.

Anthos Therapeutics announced abelacimab, a fully human monoclonal antibody inhibiting factor XI, received fast track designation from the FDA for an indication to prevent stroke and systemic embolism in patients with atrial fibrillation.

Levetiracetam was safe and may be effective in preventing acute seizures in patients with spontaneous intracerebral hemorrhage, according to clinical trial results in The Lancet Neurology.

Asundexian on top of dual antiplatelet therapy successfully reduced factor XIa activity after acute MI and stroke with no excess bleeding risk, two speakers reported.

History of stroke was associated with increased odds of cognitive impairment in both non-Hispanic white and Mexican American individuals, researchers reported.

Implantable loop recorder screening for atrial fibrillation did not significantly reduce the risk for stroke compared with usual care, according to study results published in JAMA Neurology.

In the U.S., the use of carotid artery stenting has never been as widespread as that of carotid endarterectomy, which is partly a function of the CMS coverage decision. That may be about to change.

In the AXIOMATIC-SSP trial, milvexian, a novel factor XIa inhibitor, was protective against ischemic stroke with no increased risk for intracranial hemorrhage compared with placebo in patients requiring secondary prevention.

Although thrombectomy was linked with improved functional recovery in patients with pre-stroke disability, it might also increase the risk for survival with significant disability, according to a study in JAMA Network Open.